Literature DB >> 4068186

Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study.

F N Brand, R D Abbott, W B Kannel, P A Wolf.   

Abstract

In 30 years of follow-up of 5,209 participants in the Framingham Study, 193 men and 183 women developed atrial fibrillation (AF). Among this group, "lone" AF occurred in 32 men and 11 women free of coronary heart disease, congestive heart failure, rheumatic heart disease, and hypertensive cardiovascular disease. To determine the characteristics and prognosis of lone AF, each case was matched to controls in the remaining Framingham sample. Comparisons indicated that levels of several risk factors associated with coronary heart disease were similar between the two groups. Atrial fibrillation cases, however, had significantly higher rates of preexisting nonspecific T- or ST-wave abnormalities and intraventricular block as determined by electrocardiograms. Follow-up for new cardiovascular events indicated similar rates of coronary heart disease and congestive heart failure, but the rate of strokes was significantly greater in the lone AF group. Findings suggest that subjects with lone AF, despite similar cardiovascular risk profiles to normal controls, have a distinct preponderance of preexisting electrocardiographic abnormalities. Furthermore, contrary to general belief, lone AF is not a benign condition; it has a serious prognosis, indicating a greater need for detection and treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4068186

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  85 in total

Review 1.  Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis.

Authors:  S L Kopecky
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 2.  Chronic and paroxysmal atrial fibrillation: course, prognosis, and stroke risk.

Authors:  T E Cuddy
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

Review 4.  Mechanisms underlying the development of atrial arrhythmias in heart failure.

Authors:  Vias Markides; Nicholas S Peters
Journal:  Heart Fail Rev       Date:  2002-07       Impact factor: 4.214

Review 5.  [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

Authors:  M Hammwöhner; A D'Alessandro; D Dobrev; P Kirchhof; A Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

6.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Synchronised cardioversion for chronic atrail fibrillation.

Authors:  E Aniteye; D Kotei; M Tettey; L Sereboe; F Edwin; A Doku; M Tamatey; K Entsuah-Mensah; S Batista; K Frimpong-Boateng
Journal:  Ghana Med J       Date:  2008-03

Review 8.  Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies.

Authors:  Mark A Crandall; David J Bradley; Douglas L Packer; Samuel J Asirvatham
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 9.  Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.

Authors:  Gerald V Naccarelli; John Hynes; Deborah L Wolbrette; Luna Bhatta; Mazhar Khan; Jerry Luck
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

Review 10.  Optimal management of older patients with atrial fibrillation.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.